SUMMARY Serial measurements of 51Cr edetic acid clearance were made over a period of one year in two groups of 8 children, in a double blind trial of la-hydroxycholecalciferol (10 ng/kg/day) and calciferol (670 ng/kg/day). Glomerular filtration rate (GFR) at the beginning of the trial was 20-50 ml/min/1 -73 M2; it rose in the children given a-hydroxycholecalciferol (group A) after 6 months but was not appreciably different from the pretreatment value after 12 months. The'GFR in the children given calciferol (group B) showed no significant difference at 6 or 12 months. 
It has been suggested that 1 oc-hydroxycholecalciferol (1 oc OHCC) may cause deterioration in renal function in patients with advanced renal failure.1-4 1 oc OHCC remains the most available of the potent vitamin D analogues but some clinicians limit its use to severe symptomatic renal bone disease because of the risk of deterioration in renal function.3 56 Nielson5 studied for 6 months the effects of 1 oc OHCC on 9 patients with advanced renal failure who had not received dialysis. He 4 . PTH was suppressed significantly at 6 months by 1 c OHCC, P<001, but rose subsequently at 12 months with no significant difference between the two groups at that time.
Total serum alkaline phosphatase, alkaline phosphatase bone isoenzyme, urine calcium/creatinine ratio, and bone mineral density showed no significant difference between or within the groups throughout the study.
Two patients in group A and one in group B had radiological evidence of hyperparathyroidism with subperiostal erosions over the middle phalanges at the beginning of the trial. Repeat bone radiographs were normal in the two patients in group A at 6 and 12 months, but showed deterioration of the hyperparathyroid lesions in the patient in group B. In group A 62-5 % had abnormal bone histology with woven osteoid, increased osteoid seams, and trabecular osteoid volume at the beginning of ,ug 1 a OHCC daily for 6 months. They all had abnormal bone histology before treatment, but after there was complete healing of the osteopathy. No reference was made, however, to the state of their renal function after treatment.
The patients in this study had moderate but stable renal function that showed no deterioration during 1 a OHCC treatment. It is possible that the effect of 1 cx OHCC on renal function is related to the severity of renal impairment at the start of treatment and patients with moderate but stable renal function may not therefore be as adversely affected as those with severe renal impairment.
One patient in group A had an appreciable fall in GFR after 7 months of treatment, but this subsequently returned to near pretreatment value with no change in treatment. This patient had been on propranolol which was stopped after three months on 1 a OHCC because of profound bradycardia. 
